Core Insights - BioCardia, Inc. has been granted US Patent No. 12,311,127 for its "Radial and Trans-endocardial Delivery Catheter" technology, which focuses on minimally invasive interventional catheter systems for delivering biologic therapies to the heart [1][2]. Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics aimed at treating cardiovascular and pulmonary diseases, with its headquarters in Sunnyvale, California [4]. - The company is developing two main biotherapeutic platforms: CardiAMP autologous and CardiALLO™ allogeneic cell therapies, with three clinical stage product candidates currently in development [4]. Technology and Innovation - The patented helical needle-tipped catheter technology is designed to provide optimal, site-specific treatment while minimizing off-target toxicities and avoiding surgical access to the heart [2]. - The Helix catheter system is integral to the safety and efficacy of the CardiAMP Cell Therapy development program, which aims to improve outcomes for patients with ischemic cardiomyopathies and refractory angina [3]. Future Developments - BioCardia is actively pursuing separate approvals for both the CardiAMP Cell Therapy and the Helix biotherapeutic delivery system, which is expected to facilitate a smooth transition from research to commercialization [3].